Abstract
The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized by large biological heterogeneity with variable clinical outcomes. Here, we performed a large integrative multi-omics analysis of patients diagnosed with NMIBC (n=834). Transcriptomic analysis identified four classes (1, 2a, 2b and 3) reflecting tumor biology and disease aggressiveness. Both transcriptome-based subtyping and the level of chromosomal instability provided independent prognostic value beyond established prognostic clinicopathological parameters. High chromosomal instability, p53-pathway disruption and APOBEC-related mutations were significantly associated with transcriptomic class 2a and poor outcome. RNA-derived immune cell infiltration was associated with chromosomally unstable tumors and enriched in class 2b. Spatial proteomics analysis confirmed the higher infiltration of class 2b tumors and demonstrated an association between higher immune cell infiltration and lower recurrence rates. Finally, a single-sample classification tool was built and the independent prognostic value of the transcriptomic classes was documented in 1306 validation samples. The classifier provides a framework for novel biomarker discovery and for optimizing treatment and surveillance in next-generation clinical trials.
Competing Interest Statement
L.D. has sponsored research agreements with C2i-genomics, Natera, AstraZeneca and Ferring, and has an advisory/consulting role at Ferring. J.B.J. has sponsored research agreements with Medac, Photocure ASA, Cephaid, Nucleix, Astellas and Ferring, and has an advisory board role at Olympus Europe, Cephaid and Ferring. J.D.R. is involved in a sponsored scientific study or trial with Pacific Edge Biotechnologies, MDxHealth and Urogen Pharma, is a consultant for Urogen Pharma, and has an investment interest in American Kidney Stone Management. J. J. M. is a consultant for Ferring, AstraZeneca, Janssen and participated in advisory boards for Foundation Medicine and Nucleix.
Funding Statement
Funding: SVL, FFP, and LD are supported by the following funding sources: Aarhus University, The Danish Cancer Biobank, The Health Research Foundation of Central Denmark Region, The Danish Cancer Society. NM and FXR are supported by Fondo de Investigaciones Sanitarias (FIS), Instituto de Salud Carlos III, Spain (#PI18/01347), Asociacion Espanola Contra el Cancer (AECC, # GB28012014). DJD is supported by the following funding sources: RSG 17 233 01 TBE from the American Cancer Society, the W.W. Smith Charitable Trust, the Pennsylvania Department of Health via Tobacco CURE Funds, the Ken and Bonnie Shockey Fund for Urologic Research and the Bladder Cancer Support Group at Penn State Health. JIW is supported by the Laurence M. Demers Career Development Professorship in Pathology and Medicine, Pennsylvania State University. JDR is supported by the Ken and Bonnie Shockey Fund for Urologic Research at Penn State Health. JM is funded by a SEED Award from the HOPE Foundation, the Department of Defense (W81XWH-18-0257), and the VHA (BX003692-01). Ethichal review boards: The study was approved by the Central Denmark Region Committees on Biomedical Research Ethics (#1994/2920; Skejby, Aalborg, Frederiksberg); the Danish National Committee on Health Research Ethics (#1906019), the ethics committee of the University Hospital Erlangen (#3755); the ethics committee of the Technical University of Munich (#2792/10); Medical Ethics Committee of Erasmus MC (MEC#168.922/1998/55; Rotterdam); the Uppsala Region Committee on Biomedical Research Ethics (#2008/252); the Ethical Committee of Faculty of Medicine, University of Belgrade (#440/VI-7); the Ethics Committee (CEIC) of Institut Municipal dAssistencia Sanitaria/Hospital del Mar (2008/3296/I); the ethics committee of the University Hospital Jena (#4774-4/16).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Normalized RNA read counts (accession# to be included, submission in progress) and SNP microarray data (accession# to be included, submission in progress) are deposited at the European Bioinformatics Institute (EMBL-EBI) Array Express. Raw sequencing data is deposited at The European Genome-phenome Archive (EGA) under accession numbers EGAS00001001236 and EGASxx (submission in progress). There are restrictions to the availability of raw sequencing data deposited at EGA due to Danish legislation regarding sharing and processing of sensitive personal data. Data can be shared if the new research purposes proposed by the data importers are approved by the National Committee on Health Research Ethics in Denmark. Furthermore, data processor agreements and contracts need to be signed to fulfil European GDPR data sharing rules. The lead contact will accommodate reasonable requests. Processed (non-sensitive) data will be shared upon request without restrictions.
